Biotinylated Human IFN alpha/beta R2 Protein 2021

$525.00 – $1,750.00

Summary

Expression: HEK293
Binding assay: Yes (SPR)
Amino Acid Range: Ile27-Lys243

SKU: 2021parent Categories: proteins, Recombinant proteins Tag: active proteins

Weight	1 lbs
Dimensions	9 × 5 × 2 in
express system	HEK293
product tag	C-His-Avi
purity	> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC
background	Although interferon (IFN)-α is known to exert immunomodulatory and antiproliferative effects on dendritic cells (DCs) through induction of protein-coding IFN-stimulated genes (ISGs), little is known about IFN-α-regulated miRNAs in DCs. Since several miRNAs are involved in regulating DC functions, it is important to investigate whether IFN-α's effects on DCs are mediated through miRNAs as well.
molecular weight	The protein has a predicted MW of 27.66 kDa. Due to glycosylation, the protein migrates to 42-52 kDa based on Tris-Bis PAGE result.
available size	100 µg, 500 µg
endotoxin	Less than 1EU per μg by the LAL method.

Biotinylated Human IFN alpha/beta R2 Protein 2021

protein

Size and concentration 100, 500µg and lyophilized
Form Lyophilized
Storage Instructions Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Storage buffer Shipped at ambient temperature.
Purity > 95% as determined by Tris-Bis PAGE

target relevance
Although interferon (IFN)-α is known to exert immunomodulatory and antiproliferative effects on dendritic cells (DCs) through induction of protein-coding IFN-stimulated genes (ISGs), little is known about IFN-α-regulated miRNAs in DCs. Since several miRNAs are involved in regulating DC functions, it is important to investigate whether IFN-α's effects on DCs are mediated through miRNAs as well.
Protein names Interferon alpha/beta receptor 2 (IFN-R-2) (IFN-alpha binding protein) (IFN-alpha/beta receptor 2) (Interferon alpha binding protein) (Type I interferon receptor 2)
Gene names IFNAR2,IFNAR2 IFNABR IFNARB
Protein family Type II cytokine receptor family
Mass 9606Da
Function Together with IFNAR1, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa) (PubMed:10049744, PubMed:10556041, PubMed:21854986, PubMed:26424569, PubMed:28165510, PubMed:32972995, PubMed:7665574, PubMed:7759950, PubMed:8181059, PubMed:8798579, PubMed:8969169). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response (PubMed:10049744, PubMed:17517919, PubMed:21854986, PubMed:26424569, PubMed:28165510, PubMed:32972995, PubMed:7665574, PubMed:7759950, PubMed:8181059, PubMed:8798579, PubMed:8969169). Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another (PubMed:10556041, PubMed:11682488, PubMed:12105218, PubMed:21854986, PubMed:32972995). The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors (STAT1, STAT2 and STAT) (PubMed:11682488, PubMed:12105218, PubMed:21854986, PubMed:32972995). STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes (PubMed:12105218, PubMed:28165510, PubMed:9121453).; [Isoform 3]: Potent inhibitor of type I IFN receptor activity.
Subellular location [Isoform 1]: Cell membrane ; Single-pass type I membrane protein .; [Isoform 2]: Cell membrane ; Single-pass type I membrane protein .; [Isoform 3]: Secreted .
Tissues Isoform 3 is detected in the urine (at protein level) (PubMed:7759950, PubMed:8181059). Expressed in blood cells. Expressed in lymphoblastoid and fibrosarcoma cell lines.
Structure Heterodimer with IFNAR1; forming the receptor for type I interferon (PubMed:10049744, PubMed:21854986, PubMed:24075985, PubMed:7665574, PubMed:8181059). Interacts with JAK1 (PubMed:7759950, PubMed:8181059). Interacts with the transcriptional factors STAT1 and STAT2 (PubMed:28165510, PubMed:9121453). Interacts with USP18; indirectly via STAT2, it negatively regulates the assembly of the ternary interferon-IFNAR1-IFNAR2 complex and therefore type I interferon signaling (PubMed:28165510).
Post-translational modification Phosphorylated on tyrosine residues upon interferon binding. Phosphorylation at Tyr-337 or Tyr-512 are sufficient to mediate interferon dependent activation of STAT1, STAT2 and STAT3 leading to antiproliferative effects on many different cell types.; Glycosylated.
Target Relevance information above includes information from UniProt accession: P48551
The UniProt Consortium

SPR with Biotinylated Human IFN alpha/beta R2 Protein

Biotinylated Human IFN alpha/beta R2, His-Avi Tag captured on CM5 Chip via anti-his antibody can bind Human IFN alpha 1, hFc Tag with an affinity constant of 24.2 nM as determined in SPR assay (Biacore T200).

HPLC of Biotinylated Human IFN alpha/beta R2 Protein

The purity of Biotinylated Human IFN alpha/beta R2 is greater than 95% as determined by SEC-HPLC.

SDS-PAGE gel of Biotinylated Human IFN alpha/beta R2 Protein

Biotinylated Human IFN alpha/beta R2 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.